Open Label Two-Arm Study to Evaluate Rilzabrutinib (PRN1008) in IgG4-Related Disease Patients
Status:
Recruiting
Trial end date:
2023-12-05
Target enrollment:
Participant gender:
Summary
PRN1008-017 is a Phase 2a, multi-center, open-label, two-arm study of approximately 25
patients with active IgG4-related disease (IgG4-RD). The two arms include (1) Experimental:
PRN1008 with glucocorticoids and (2) Active Comparator: glucocorticoids only.
Phase:
Phase 2
Details
Lead Sponsor:
Principia Biopharma Inc. Principia Biopharma, a Sanofi Company